These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 3045130)

  • 1. Immunotoxins against solid tumors.
    Pirker R
    J Cancer Res Clin Oncol; 1988; 114(4):385-93. PubMed ID: 3045130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotoxins: a clinical review of their use in the treatment of malignancies.
    Hertler AA; Frankel AE
    J Clin Oncol; 1989 Dec; 7(12):1932-42. PubMed ID: 2685183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic use of immunotoxins.
    Cobb PW; LeMaistre CF
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):6-13. PubMed ID: 1509295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotoxin treatment of cancer.
    Pastan I; Hassan R; FitzGerald DJ; Kreitman RJ
    Annu Rev Med; 2007; 58():221-37. PubMed ID: 17059365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
    Mathew M; Verma RS
    Cancer Sci; 2009 Aug; 100(8):1359-65. PubMed ID: 19459847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted toxins as anticancer agents.
    Siegall CB
    Cancer; 1994 Aug; 74(3 Suppl):1006-12. PubMed ID: 7913661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?].
    Engert A; Gottstein C; Winkler U; Schön G; Amlot P; Thorpe P; Diehl V
    Med Klin (Munich); 1992 Oct; 87(10):503-9. PubMed ID: 1461215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.
    Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
    Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
    Seon BK; Matsuno F; Haruta Y; Kondo M; Barcos M
    Clin Cancer Res; 1997 Jul; 3(7):1031-44. PubMed ID: 9815781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel method to purify immunotoxins from free antibodies using modified recombinant toxins.
    Dhanabal M; Fryxell DK; Ramakrishnan S
    J Immunol Methods; 1995 Jun; 182(2):165-75. PubMed ID: 7790724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin.
    Roy DC; Ouellet S; Le Houillier C; Ariniello PD; Perreault C; Lambert JM
    J Natl Cancer Inst; 1996 Aug; 88(16):1136-45. PubMed ID: 8757193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective tumor targeting: strategies for the delivery of Armed Antibodies.
    MacDonald GC; Glover N
    Curr Opin Drug Discov Devel; 2005 Mar; 8(2):177-83. PubMed ID: 15782542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids.
    Wenning LA; Murphy RM
    Biotechnol Bioeng; 1999 Mar; 62(5):562-75. PubMed ID: 10099565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotoxins.
    Press OW
    Biotherapy; 1991; 3(1):65-76. PubMed ID: 2009215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for the clinical use of immunotoxins: monoclonal antibodies conjugated to ribosome-inactivating proteins.
    Preijers FW
    Leuk Lymphoma; 1993 Mar; 9(4-5):293-304. PubMed ID: 8348066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent progress on tumor missile therapy and tumor vascular targeting therapy as a new approach.
    Yoshioka Y; Tsutsumi Y; Nakagawa S; Mayumi T
    Curr Vasc Pharmacol; 2004 Jul; 2(3):259-70. PubMed ID: 15320824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin.
    Zovickian J; Johnson VG; Youle RJ
    J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotoxin therapy of cancer.
    Frankel AE
    Oncology (Williston Park); 1993 May; 7(5):69-78; discussion 79-80, 83-6. PubMed ID: 8512787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotoxins to the murine transferrin receptor: intracavitary therapy of mice bearing syngeneic peritoneal tumors.
    Bjorn MJ; Groetsema G
    Cancer Res; 1987 Dec; 47(24 Pt 1):6639-45. PubMed ID: 3499979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin.
    Uckun FM; Myers DE; Irvin JD; Kuebelbeck VM; Finnegan D; Chelstrom LM; Houston LL
    Leuk Lymphoma; 1993 Apr; 9(6):459-76. PubMed ID: 7687916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.